Thrombomodulin (CD141)

conclusion regarding usefulness

adenocarcinoma

mesothelioma

Fink 199220

yes

1/15

8/8

Collins 19922

yes

4/48(All cases were pulmonary adenocarcinomas.)

31/31

Brown 19933

no

62/103(All cases were pulmonary adenocarcinomas.)

20/34(all cases were epithelial pleural mesotheliomas.)

Ascoli 1995(study done on cytospin preparations and cell blocks)4

yes

44/119(Various sites of origin. Positivity was cytoplasmic. Also, all of the squamous carcinomas were positive.)

33/33(There was thick membrane positivity.)

Attanoos 19955

1/20(All cases were renal carcinomas.)

11/20(10/14 epithelial mesotheliomas were positive)

Attanoos 19966

yes

2/32(All cases were pulmonary primary adenocarcinomas.)

22/42(including positivity in 8/12 pure epithelial-type mesotheliomas of the pleura and in all 4 papillary epithelial peritoneal mesotheliomas.)

Doglioni 19967

no

17/22(All cases were pulmonary primary adenocarcinomas.)

16/20

Dejmek 19978

10/43

69/110 

Kennedy 19979

yes

8 /63(6/23 cases of carcinoma metastatic to pleura from various sites[2 strong, 5-70% of cells and 2 strong, <5% of cells], 1/20 primary ovarian cell carcinomas, and 1/20 primary renal cell carcinomas [strong, >70% of cells]. )

49/57(All cases were pleural mesotheliomas, 47 epithelioid and 10 sarcomatoid. The sarcomatoid cases were mostly negative)

Ordonez 199710

yes

7/46(All cases were pulmonary adenocarcinomas: 3 cases 50-75% of cells, 2 cases 1-25% of cells, 2 cases trace only)

32/42(28/35 epithelioid, 3/4 biphasic, 1/3 sarcomatoid. 4 cases > 75% of cells, 8 cases 50-75% of cells, 10 cases 25-50% of cells, 6 cases 1-25% of cells)

Riera 199711

no

13/211(adenocarcinomas of various origins)

28/57(cases were epitheloid mesotheliomas.)

Ordonez 199812

yes

1/45(30 ovarian (10 primary and 20 metastatic to the peritoneum) and 15 primary papillary serous carcinomas of the peritoneum)

26/35(All epithelial peritoneal mesotheliomas.)

Chenard-Neu 199813

no

4/30(adenocarcinomas of various origins)

12/28(various histological types)

Fetsch 1998(This study was of malignant effusions.)14

no

21/40(8/13 breast, 2/6 ovarian, 1/4 prostatic, 4/8 lung and 6/9 gastrointestinal adenocarcinomas were positive.)

24/36

Cury 200015

yes

12/63(lung = 19; breast = 21; ovary = 6; colon = 10; kidney = 4; uterus, epididymis, pancreas = 1 case each)

55/61

Brockstedt 200016

yes

13/57(adenocarcinomas of various origins)

74/119

Roberts 200026

no

2/18(adenocarcinomas of various origins)

25/82

Carella 200117

yes

1/20(All cases were pulmonary adenocarcinomas)

29/46(various histological types)

Harper 2001(Note that this is not a peer-reviewed paper.)18

2/18

32/112

Comin 200121

yes

5/23(All cases were pulmonary adenocarcinomas)

39/42

Foster 200125

no

4/51(All cases were pulmonary adenocarcinomas: in the 4 positive cases, staining was less than 50%, weak to intermediate)

23/67(various histological types: only 8 cases showed more than 50% staining)

Miettinen 200323

not studied

25/28(20/21 epithelioid [embrane staining], 5/7 sarcomatoid)

Miettinen 200323

32/256

16/27(9 of 10 tubulopapillary, 4 of 5 combined tubulopapillary and poorly differentiated and 3 of 12 poorly differentiated solid epithelial tumours)

Abutaily 2002 24

2/35(All cases were pulmonary adenocarcinomas. Cell membrane staining)

22/41(cell membrane staining)

Ordonez 200327

no

7/50(All cases were pulmonary adenocarcinomas. 5 cases showed positivty of 1-25% of cells and 2 cases <1% of cells)

46/60(epithelioid mesotheliomas: in 3 cases >75% of cells stained, in 16 cases 50-75% of cells stained), in 16 cases 25-50% of cells stained, in 10 cases 1-25% of cells stained)

Overall

Limited

19% (273/1428)

62% (767/1238)

adenocarcinoma

acinar type, differentiated

19/148(17 cases showed more than 10% of tumour cells positive, 2 cases showed less than 10% of tumour cells positive.) 23

acinar type, solid, poorly-differentiated, mucin-positive

7/49(7 cases showed more than 10% of tumour cells positive.)  23

bronchoalveolar, mucinous

1/6(1 case showed more than 10% of tumour cells positive.) 23

bronchoalveolar, non-mucinous

1/7(1 case showed more than 10% of tumour cells positive.) 23

acinar with focal neuroendocrine differentiation

0/22 23

neuroendocrine

3/18(3 cases showed more than 10% of tumour cells positive.) 23

clear cell

1/6(1 case showed more than 10% of tumour cells positive.) 23

large cell

NOS

29/117(26 cases showed more than 10% of tumour cells positive, 3 cases showed less than 10% of tumour cells positive.) 23

with focal neuroendocrine differentiation

3/10(2 cases showed more than 10% of tumour cells positive, 1 cases showed less than 10% of tumour cells positive.) 23

neuroendocrine carcinoma

6/33(5 cases showed more than 10% of tumour cells positive, 1 cases showed less than 10% of tumour cells positive.) 23

small cell carcinoma

11/41(4 cases showed more than 10% of tumour cells positive, 7 cases showed less than 10% of tumour cells positive.) 23

squamous cell

keratinising

62/62(61 cases showed more than 10% of tumour cells positive: staining was typically extensive with membrane accentuation, 1 cases showed less than 10% of tumour cells positive.) 23

non-keratinising

54/62(47 cases showed more than 10% of tumour cells positive, 7 cases showed less than 10% of tumour cells positive.) 23

NOS

33/331

sarcomatoid carcinoma, spindle cell

1/6(1 case showed less than 10% of tumour cells positive.) 23

giant cell carcinoma

3/6(2 cases showed more than 10% of tumour cells positive, 1 cases showed less than 10% of tumour cells positive.) 23